337.60 -0.63 (-0.19%)
After hours: 4:06PM EDT
|Bid||338.24 x 800|
|Ask||338.45 x 900|
|Day's Range||334.68 - 342.27|
|52 Week Range||249.17 - 388.67|
|Beta (3Y Monthly)||1.53|
|PE Ratio (TTM)||24.02|
|Earnings Date||Oct 23, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||392.16|
The honorees include several MIT researchers and the developers of a drug sold by Cambridge-based Biogen.
LONDON (Reuters) - South Korea's Samsung Bioepis and its partner Biogen (BIIB.O) have launched a third rival to AbbVie's (ABBV.N) blockbuster medicine Humira in Europe, ramping up competition for a slice ...
South Korea's Samsung Bioepis and its partner Biogen have launched a third rival to AbbVie's blockbuster medicine Humira in Europe, ramping up competition for a slice of the world's top-selling prescription drug's sales. A fourth so-called biosimilar copy of Humira is expected soon from Mylan . The primary European patent on Humira expired on Oct. 16, opening the door to cheaper near-identical copies for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis.
CAMBRIDGE, Mass. & INCHEON, Korea-- -- IMRALDI TM , a biosimilar referencing HUMIRA ® i , is the third anti-TNF biosimilar developed by Samsung Bioepis to be commercialized by Biogen across Europe, following BENEPALI TM and FLIXABI TM Biogen and Samsung Bioepis were the first in Europe to receive approvals for biosimilars referencing the three most prescribed anti-TNF medicines in Europe. Biogen and ...
IMRALDITM is approved in the European Union for the same 14 complex autoimmune conditions as its reference product In 2017 Biogen became the first company in Europe with.
Of the 23 analysts covering Sarepta Therapeutics (SRPT) in October, eight analysts gave the stock a “strong buy” rating, 14 analysts gave it a “buy” rating, and one analyst gave Sarepta Therapeutics a “hold” rating.
Sarepta Therapeutics (SRPT) has a sponsored research and exclusive license option agreement with Genethon for advancing the latter’s microdystrophin gene therapy program. Sarepta also has a sponsored research and exclusive license option agreement with Duke University for advancing its gene-editing CRISPR/Cas9 technology for muscular dystrophy. Sarepta had submitted a marketing authorization application (or MAA) for eteplirsen to the European Medicines Agency (or EMA) in November 2016.
Sarepta Therapeutics (SRPT) is working with several strategic partners for developing multiple treatment approaches to DMD. These partners include Nationwide Children’s Hospital, Myonexus, Genethon, Duke University, and Summit Limited.
Sarepta Therapeutics’ (SRPT) Exondys 51 uses exon-skipping technology to skip exon 51 of the DMD gene. The drug is designed to bind to exon 51, which leads to an exclusion or skipping of this exon during mRNA processing. Golodirsen uses exon-skipping technology to skip exon 53 of the DMD gene.
Sarepta Therapeutics’ (SRPT) cost of sales increased from $506,000 in the second quarter of 2017 to $6.73 million in the second quarter. Sarepta’s cost of sales primarily consists of inventory costs, overhead costs, and royalty payments to BioMarin Pharmaceutical (BMRN). These royalty payments resulted from the settlement and licenses agreements in July 2017. Sarepta Therapeutics’ gross income increased from $34.48 million in the second quarter of 2017 to $66.8 million in the second quarter.
On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x. Its forward EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiple, a capital-structure-neutral valuation measure, is 10.4x, which is higher than the industry average of 9.4x. A company’s forward PE ratio reflects the market’s views in regards to the company’s growth potential over the next 12 months.
Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.
Through its research initiatives, Biogen Inc. (BIIB) aims to identify new ways to manage and monitor multiple sclerosis (MS) disease progression and provide physicians with real-world evidence to help inform treatment decisions. Data show serum neurofilament light (sNfL) is a potential biomarker of disease activity and treatment response, and results from MS PATHS (Multiple Sclerosis Partners Advancing Technology and Health Solutions) support the use of technology to broadly monitor for clinically important outcomes, including cognitive changes.
Wall Street analysts expect Celgene to report a net income and EPS of $1.2 billion and $1.71, respectively, in the third quarter.
Neurocrine Biosciences’ (NBIX) revenues grew from $6.3 million in the second quarter of 2017 to $96.9 million in the second quarter. The company reported net revenues of $168.0 million in the first half of this year, which grew from $6.3 million in the first half of 2017. Wall Street analysts expect Neurocrine Biosciences to generate revenues of $151.8 million in the third quarter.
Biogen (BIIB) and Eisai have collaborated to jointly develop and commercialize therapies for Alzheimer’s disease. Eisai took the lead in co-developing a BACE inhibitor, elenbecestat, and an anti-amyloid beta protofibril antibody, BAN2401. Biogen took the lead in co-development of an anti-amyloid beta antibody, aducanumab.
The best mutual funds have been heavily buying medical, transportation and retail stocks recently, with CVS, Biogen and Lowe's among the recipients.
Biogen Inc. (BIIB) today announced new interim results from NURTURE, an ongoing open-label, single-arm efficacy and safety study of SPINRAZA® (nusinersen) in 25 presymptomatic infants with SMA. The data are being presented today in a late-breaking session at the 23rd Annual Congress of the World Muscle Society (WMS) held in Mendoza, Argentina.
A former Biogen Inc. employee has filed a lawsuit accusing the company of failing to accommodate his Parkinson's disease — even as it was developing a drug for the condition. In the suit, which was filed in federal court late last month, Norwood resident and former IT staff member Aldrin Carao claims that Biogen (Nasdaq: BIIB) discriminated against him and backtracked on accommodations it had made for his disease before abruptly firing him in February 2016. Meanwhile, Carao says, the Cambridge biotech was developing a drug for early Parkinson's disease.
Allergan’s (AGN) product portfolio includes generic pharmaceutical products and specialty pharmaceutical products. The company’s business comprises three segments—US General Medicines, US Specialized Therapeutics, and International. The chart below compares Allergan’s revenues and EPS since the first quarter of 2017, as well as its estimates for the third quarter.
The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy. THE GLOBE AND MAIL ** Canadian children with a rare and ...